Boston Trust Walden Corp Trims Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Boston Trust Walden Corp reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 810 shares of the pharmaceutical company’s stock after selling 150 shares during the quarter. Boston Trust Walden Corp’s holdings in Vertex Pharmaceuticals were worth $326,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Mutual Advisors LLC boosted its position in Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock valued at $1,751,000 after buying an additional 21 shares during the period. Daymark Wealth Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock valued at $374,000 after purchasing an additional 22 shares during the period. Grove Bank & Trust grew its stake in Vertex Pharmaceuticals by 5.7% in the third quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock worth $191,000 after purchasing an additional 22 shares in the last quarter. Outlook Wealth Advisors LLC increased its holdings in Vertex Pharmaceuticals by 2.8% during the 3rd quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock worth $415,000 after purchasing an additional 24 shares during the period. Finally, Dunhill Financial LLC raised its position in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the topic of several research reports. StockNews.com lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Bank of America cut their target price on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research report on Thursday, December 19th. HC Wainwright upped their price target on shares of Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Piper Sandler cut their price objective on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Finally, Royal Bank of Canada upped their target price on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $502.58.

Vertex Pharmaceuticals Stock Up 2.5 %

Vertex Pharmaceuticals stock opened at $482.28 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The firm has a 50 day moving average price of $434.73 and a 200 day moving average price of $462.62. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a market capitalization of $124.20 billion, a PE ratio of -242.35, a price-to-earnings-growth ratio of 2.39 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the previous year, the business earned $3.67 EPS. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. Research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.